Deal Watch: AbbVie and Boehringer Ingelheim Collaborate on Biologic for Psoriasis

Deal Watch

On March 7, 2016, AbbVie and Boehringer Ingelheim announced that they have entered into a global collaboration to develop BI 655066, an anti-IL-23 monoclonal biologic antibody that is in Phase 3 development for psoriasis and also being evaluated as a treatment for Crohn’s disease, psoriatic arthritis and asthma.  As part of the license agreement, AbbVie is receiving certain rights to another biologic agent, BI 655064, an anti-CD-40 antibody currently in Phase 1 development.  The companies report that, as financial consideration, AbbVie will make an initial upfront payment of $595 million, and Boehringer Ingelheim will be eligible to receive additional payments if other benchmarks are met.

Stay tuned to the Big Molecule Watch for further developments.

 

Download PDF

Comments are closed.